Heidelberg Pharma AG (HPHA.DE)
EUR 2.38
(-0.42%)
EUR 2.38
(-0.42%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 9.85 Million EUR | -46.75% |
| 2022 | 18.51 Million EUR | 958.05% |
| 2021 | 1.74 Million EUR | -79.38% |
| 2020 | 8.48 Million EUR | 16.13% |
| 2019 | 7.3 Million EUR | 99.26% |
| 2018 | 3.66 Million EUR | 93.05% |
| 2017 | 1.9 Million EUR | 39.5% |
| 2016 | 1.36 Million EUR | -40.37% |
| 2015 | 2.28 Million EUR | -36.5% |
| 2014 | 3.59 Million EUR | -72.99% |
| 2013 | 13.31 Million EUR | -25.36% |
| 2012 | 17.84 Million EUR | 80.63% |
| 2011 | 9.87 Million EUR | 0.0% |
| 2010 | - EUR | -100.0% |
| 2009 | 10 Million EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.26 Million EUR | -60.71% |
| 2024 Q2 | 2.78 Million EUR | 120.06% |
| 2024 Q3 | 1.19 Million EUR | -57.21% |
| 2023 Q2 | 2.31 Million EUR | 11.65% |
| 2023 Q1 | 2.07 Million EUR | -26.41% |
| 2023 Q3 | 2.24 Million EUR | -3.17% |
| 2023 Q4 | 3.22 Million EUR | 43.73% |
| 2023 FY | 9.85 Million EUR | -46.75% |
| 2022 Q4 | 2.81 Million EUR | -25.02% |
| 2022 Q1 | 715.72 Thousand EUR | 14.64% |
| 2022 Q2 | 11.21 Million EUR | 1467.48% |
| 2022 Q3 | 3.76 Million EUR | -66.48% |
| 2022 FY | 18.51 Million EUR | 958.05% |
| 2021 Q1 | 370.28 Thousand EUR | -62.98% |
| 2021 Q3 | 307.27 Thousand EUR | -31.4% |
| 2021 Q4 | 624.31 Thousand EUR | 103.18% |
| 2021 Q2 | 447.94 Thousand EUR | 20.97% |
| 2021 FY | 1.74 Million EUR | -79.38% |
| 2020 Q1 | 1.49 Million EUR | 32.66% |
| 2020 FY | 8.48 Million EUR | 16.13% |
| 2020 Q2 | 1.62 Million EUR | 8.23% |
| 2020 Q3 | 4.36 Million EUR | 169.41% |
| 2020 Q4 | 1 Million EUR | -77.11% |
| 2019 FY | 7.3 Million EUR | 99.26% |
| 2019 Q1 | 1.07 Million EUR | 73.81% |
| 2019 Q2 | 2.68 Million EUR | 150.44% |
| 2019 Q3 | 2.42 Million EUR | -9.45% |
| 2019 Q4 | 1.12 Million EUR | -53.49% |
| 2018 Q1 | 591.97 Thousand EUR | 16.67% |
| 2018 Q2 | 1.4 Million EUR | 136.7% |
| 2018 FY | 3.66 Million EUR | 93.05% |
| 2018 Q4 | 615.98 Thousand EUR | -41.83% |
| 2018 Q3 | 1.05 Million EUR | -24.43% |
| 2017 FY | 1.9 Million EUR | 39.5% |
| 2017 Q3 | 554.93 Thousand EUR | 44.89% |
| 2017 Q4 | 507.4 Thousand EUR | -8.56% |
| 2017 Q2 | 383 Thousand EUR | -15.76% |
| 2017 Q1 | 454.66 Thousand EUR | 76.05% |
| 2016 Q2 | 455 Thousand EUR | 0.1% |
| 2016 Q3 | 193.84 Thousand EUR | -57.4% |
| 2016 FY | 1.36 Million EUR | -40.37% |
| 2016 Q1 | 454.55 Thousand EUR | -20.31% |
| 2016 Q4 | 258.25 Thousand EUR | 33.23% |
| 2015 Q2 | 932 Thousand EUR | 118.04% |
| 2015 FY | 2.28 Million EUR | -36.5% |
| 2015 Q1 | 427.43 Thousand EUR | -43.8% |
| 2015 Q4 | 570.37 Thousand EUR | 61.12% |
| 2015 Q3 | 354 Thousand EUR | -62.02% |
| 2014 FY | 3.59 Million EUR | -72.99% |
| 2014 Q4 | 760.62 Thousand EUR | -53.82% |
| 2014 Q3 | 1.64 Million EUR | 109.81% |
| 2014 Q2 | 785 Thousand EUR | 94.46% |
| 2014 Q1 | 403.69 Thousand EUR | -87.49% |
| 2013 Q4 | 3.22 Million EUR | -7.66% |
| 2013 FY | 13.31 Million EUR | -25.36% |
| 2013 Q1 | 3.32 Million EUR | -48.74% |
| 2013 Q2 | 3.27 Million EUR | -1.54% |
| 2013 Q3 | 3.49 Million EUR | 6.82% |
| 2012 FY | 17.84 Million EUR | 80.63% |
| 2012 Q1 | 3.71 Million EUR | -27.78% |
| 2012 Q2 | 3.5 Million EUR | -5.62% |
| 2012 Q3 | 4.14 Million EUR | 18.33% |
| 2012 Q4 | 6.48 Million EUR | 56.39% |
| 2011 Q1 | 71.3 Thousand EUR | 0.0% |
| 2011 Q3 | 3.37 Million EUR | 160.25% |
| 2011 Q2 | 1.29 Million EUR | 1716.73% |
| 2011 FY | 9.87 Million EUR | 0.0% |
| 2011 Q4 | 5.13 Million EUR | 52.44% |
| 2010 FY | - EUR | -100.0% |
| 2010 Q2 | 348.5 Thousand EUR | -38.21% |
| 2010 Q3 | - EUR | -100.0% |
| 2010 Q1 | 563.97 Thousand EUR | -88.72% |
| 2010 Q4 | - EUR | 0.0% |
| 2009 Q4 | 5 Million EUR | 0.0% |
| 2009 Q3 | 5 Million EUR | 648.73% |
| 2009 Q2 | 667.79 Thousand EUR | 41.95% |
| 2009 Q1 | 470.44 Thousand EUR | 0.0% |
| 2009 FY | 10 Million EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| BioNTech SE | 3.81 Billion EUR | 99.742% |
| CureVac N.V. | 53.75 Million EUR | 81.661% |
| Biotest Aktiengesellschaft | 684.6 Million EUR | 98.56% |
| Biotest Aktiengesellschaft | 684.6 Million EUR | 98.56% |
| BRAIN Biotech AG | 55.33 Million EUR | 82.183% |
| Formycon AG | 77.69 Million EUR | 87.311% |
| Medigene AG | 6.03 Million EUR | -63.389% |